Ikena Oncology and Inmagene Biopharmaceuticals announce agreement for merger
The transaction is expected to result in approximately $175 million to support further development of IMG-007
The transaction is expected to result in approximately $175 million to support further development of IMG-007
The company has received the GMP Certification after successful closure of the inspection
Merck has also decided to end the favezelimab clinical development program
Acquisition to advance company's next generation biology portfolio with internationally recognized pioneer in organoid development
A 40 minute daily Yoga routine, incorporating select asanas and pranayama, along with standard lifestyle interventions, can reduce the risk of developing diabetes by approximately 40%
Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma
GSK secures option to multiple high-value, validated Alzheimer’s-relevant targets for drug discovery, development, and commercialization
Designation was based on early efficacy data demonstrating an 83.3% (10/12) overall response rate and a 50% (6/12) complete response rate, with a well-managed safety profile in Relapsed/Refractory Hodgkin Lymphoma patients
Subscribe To Our Newsletter & Stay Updated